Matching Items (2)
Description
Alzheimer's Disease (AD) is a progressive neurodegenerative disease accounting for 50-80% of dementia cases in the country. This disease is characterized by the deposition of extracellular plaques occurring in regions of the brain important for cognitive function. A primary component of these plaques is the amyloid-beta protein. While a natively unfolded protein, amyloid-beta can misfold and aggregate generating a variety of different species including numerous different soluble oligomeric species some of which are precursors to the neurofibrillary plaques. Various of the soluble amyloid-beta oligomeric species have been shown to be toxic to cells and their presence may correlate with progression of AD. Current treatment options target the dementia symptoms, but there is no effective cure or alternative to delay the progression of the disease once it occurs. Amyloid-beta aggregates show up many years before symptoms develop, so detection of various amyloid-beta aggregate species has great promise as an early biomarker for AD. Therefore reagents that can selectively identify key early oligomeric amyloid-beta species have value both as potential diagnostics for early detection of AD and as well as therapeutics that selectively target only the toxic amyloid-beta aggregate species. Earlier work in the lab includes development of several different single chain antibody fragments (scFvs) against different oligomeric amyloid-beta species. This includes isolation of C6 scFv against human AD brain derived oligomeric amyloid-beta (Kasturirangan et al., 2013). This thesis furthers research in this direction by improving the yields and investigating the specificity of modified C6 scFv as a diagnostic for AD. It is motivated by experiments reporting low yields of the C6 scFv. We also used the C6T scFv to characterize the variation in concentration of this particular oligomeric amyloid-beta species with age in a triple transgenic AD mouse model. We also show that C6T can be used to differentiate between post-mortem human AD, Parkinson's disease (PD) and healthy human brain samples. These results indicate that C6T has potential value as a diagnostic tool for early detection of AD.
ContributorsVenkataraman, Lalitha (Author) / Sierks, Michael (Thesis advisor) / Rege, Kaushal (Committee member) / Pauken, Christine (Committee member) / Arizona State University (Publisher)
Created2013
Description
Glyphosate is the most heavily used herbicide worldwide and recent reports indicate that it may have deleterious neurological and neurodegenerative effects on human health. Here I demonstrate that glyphosate can infiltrate the brain in a dose-dependent manner in mice sub-acutely exposed to 125, 250, or 500 mg/kg/day. I also establish that glyphosate elicits a neuroinflammatory response in both the cortex and hippocampus, marked by elevation of tumor necrosis factor α (TNFα), and causes transcriptomic dysregulation of key genes involved in oligodendrocyte proliferation, maturation, and myelination. Given that both the hippocampus and the cortex are critical for learning and memory, and are affected in Alzheimer’s disease (AD), I investigate how 50 or 500 mg/kg chronic glyphosate exposure influences locomotion, anxiety-like behavior, and cognition in the APP/PS1 mouse model of AD. Results show that while glyphosate did not influence weight, appearance, locomotion, or anxiety-like behavior, learning acquisition is impaired in the place preference and reaction time tasks following 500mg/kg chronic exposure. Additionally, I report a strong increase in water consumption in glyphosate-exposed mice, demonstrating that chronic glyphosate exposure induces polydipsia. To ascertain whether glyphosate influences AD pathogenesis, I examine neuropathological changes following chronic daily oral exposure to 50 or 500 mg/kg glyphosate. Post-mortem analysis of amyloid-beta (Aβ) in APP/PS1 hippocampal and cortical tissue show that 50 or 500 mg/kg of glyphosate elevates soluble and insoluble Aβ1-40 and Aβ1-42 in both sexes, with females showing higher levels. Further analysis of cortical TNFα levels in chronically exposed APP/PS1 mice and littermate controls confirms a neuroinflammatory response. I report no differences in amyloid precursor protein (APP) processing pathway components, CA1 NeuN+ neuronal number, relative density of Iba1+ microglia in the hippocampus, or relative density of MBP+ oligodendrocytes in the fimbria. I also show that 50mg/kg chronic glyphosate exposure elevates hemoglobin A1c levels, indicating disruptions in glucose metabolism that may be tied to polydipsia. Collectively, these results indicate that glyphosate crosses the blood-brain barrier, induces a neuroinflammatory response, and exacerbates amyloid pathology. Ultimately, these findings provide important insight into the concerns surrounding the neurological implications of glyphosate exposure.
ContributorsWinstone, Joanna (Author) / Velazquez, Ramon (Thesis advisor) / Newbern, Jason M (Committee member) / Huentelman, Matthew J (Committee member) / Leung, Maxwell (Committee member) / Coleman, Paul D (Committee member) / Arizona State University (Publisher)
Created2023